Last reviewed · How we verify

NCT04544111

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Active, enrolled Phase 2 Last updated 7 October 2025
What this trial tests

Phase 2 trial testing Trametinib in Thyroid Cancer in 19 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
2 September 2020
Primary endpoint
2 September 2026
2 September 2026

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment19
Start date2 September 2020
Primary completion2 September 2026
Estimated completion2 September 2026
Sites7 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Thyroid Cancer or Thyroid Cancer, Follicular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
    Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829
  2. Molecular features of aggressive thyroid cancer.
    Elia G, Patrizio A, Ragusa F, Paparo SR, et al · · 2022 · cited 26× · PMID 36605433 · DOI 10.3389/fonc.2022.1099280
  3. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
    Silaghi H, Lozovanu V, Georgescu CE, Pop C, et al · · 2022 · cited 23× · PMID 35408830 · DOI 10.3390/ijms23073470
  4. Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.
    Zhu L, Li XJ, Gangadaran P, Jing X, et al · · 2023 · cited 19× · PMID 37796300 · DOI 10.1007/s00262-023-03549-6
  5. The Role of the Kinase Inhibitors in Thyroid Cancers.
    Cuomo F, Giani C, Cobellis G. · · 2022 · cited 18× · PMID 35631627 · DOI 10.3390/pharmaceutics14051040
  6. Systemic treatments for radioiodine-refractory thyroid cancers.
    Chen P, Yao Y, Tan H, Li J. · · 2024 · cited 9× · PMID 39473507 · DOI 10.3389/fendo.2024.1346476
  7. Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer.
    Mishra P, Laha D, Grant R, Nilubol N. · · 2021 · cited 9× · PMID 34944814 · DOI 10.3390/cancers13246194
  8. Kinase inhibitors in thyroid cancers.
    Sukrithan V, Jain P, Shah MH, Konda B. · · 2023 · cited 7× · PMID 37434642 · DOI 10.1530/eo-22-0062

Verify or expand the search:

Other trials of Trametinib

Trials testing the same drug.

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04544111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing